CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones
of olaparib maintenance monotherapy in relapsed high grade serous ovarian cancer (HGSOC) patients (including patients with primary ...
Phase 3
Madrid, Spain and 125 other locations
followed by maintenance durvalumab and bevacizumab or durvalumab, bevacizumab and olaparib in patients with newly diagnosed advanced ovarian ...
Phase 3
Madrid, Spain and 213 other locations
in combination with paclitaxel and carboplatin (AUC4) when compared with carboplatin (AUC6) and paclitaxel alone in patients with advanced ovarian...
Phase 2
Madrid, Spain and 41 other locations
mirvetuximab soravtansine (MIRV) in patients with platinum resistant ovarian cancer. Approximately 102 patients will be enrolled in...
Phase 1
Madrid, Spain and 20 other locations
the safety and efficacy of avutometinib (VS-6766) monotherapy and in combination with defactinib in subjects with recurrent Low-Grade Serous Ovarian...
Phase 2
Madrid, Spain and 46 other locations
positive, recurrent platinum sensitive, high-grade epithelial ovarian, primary peritoneal, or fallopian tube cancer following 1 pri...
Phase 2
Madrid, Spain and 70 other locations
Olaparib Monotherapy in Patients with BRCA Mutated Ovarian Cancer following First Line Platinum Based Chemotherapy....
Phase 3
Madrid, Spain and 176 other locations
of alpelisib and olaparib compared with single agent cytotoxic chemotherapy in patients with platinum resistant or refractory high-grade serous ovarian...
Phase 3
Madrid, Spain and 102 other locations
This study will assess the safety and efficacy of avutometinib (VS-6766) in combination with defactinib versus Investigator's choice of treatments (I...
Phase 3
Madrid, Spain and 53 other locations
chemotherapy and in maintenance, in patients presenting epithelial ovarian cancer (including patients with primary peritoneal and /...
Phase 3
Madrid, Spain and 74 other locations
Clinical trials
Research sites
Resources
Legal